Walleye Capital LLC Invests $700,000 in Alumis Inc. $ALMS

Walleye Capital LLC purchased a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the first quarter, Holdings Channel reports. The fund purchased 31,778 shares of the company’s stock, valued at approximately $700,000.

Several other institutional investors and hedge funds have also modified their holdings of ALMS. KBC Group NV acquired a new position in Alumis during the first quarter worth $42,000. Strs Ohio raised its holdings in Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares in the last quarter. State of Wyoming acquired a new stake in shares of Alumis in the first quarter worth about $57,000. Assetmark Inc. acquired a new stake in shares of Alumis in the first quarter worth about $92,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after acquiring an additional 979 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wells Fargo & Company increased their price objective on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Guggenheim boosted their target price on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Chardan Capital upped their target price on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating and set a $39.00 price target on shares of Alumis in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Stock Down 1.1%

Shares of ALMS opened at $28.00 on Friday. Alumis Inc. has a 12-month low of $3.75 and a 12-month high of $31.35. The firm has a market capitalization of $3.57 billion, a price-to-earnings ratio of -14.14 and a beta of -0.73. The stock’s 50-day moving average price is $24.50 and its 200 day moving average price is $24.72.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Equities research analysts expect that Alumis Inc. will post -2.87 EPS for the current year.

Insider Activity at Alumis

In related news, insider Sanam Pangali sold 5,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the completion of the transaction, the insider directly owned 11,111 shares in the company, valued at approximately $311,108. This represents a 31.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 33.70% of the company’s stock.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.